Research Article
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
Table 2
Plasma CAIX in breast cancer patients.
| Patient population | Chemotherapy | Time points | CAIX, pg/mL | Mean | Median | Range |
| LABC | Neoadjuvant paclitaxel (T) + sunitinib (S) × 12 weeks followed by anthracycline (AC) × 15 weeks | Baseline () | 34.0 | 26.0 | 0–155 | Following T + S () | 48.4 | 28.5 | 0–239 | Following AC () | 49.6 | 42.2 | 15–172 |
| MBC | Irinotecan + etoposide or paclitaxel + immunomodulatory agent | Baseline () | 90.7 | 76.9 | 31.2–254.7 | Following 4–6 weeks of | 90.7 | 74.3 | 27.2–224 | chemotherapy () |
|
|
LABC: locally advanced breast cancer; MBC: metastatic breast cancer.
|